- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06182722
Association of Peripheral Immune Cells With Antidepressant Treatment Response
The purpose of this observational study is discovering potential biomarkers to predict antidepressant treatment response in patients with major depressive disorder (MDD) while comparing the transcriptomic changes between patients with MDD and healthy controls as well as before and after antidepressant treatment.
Eligible patients will be assessed at Week 1, Week 2, Week 4 and Week 8 while healthy normal volunteers will only be evaluated at baseline. Assessments will include the following: an interview about mental and physical health, a physical examination including drawing of venous blood samples and several psychiatric rating scales.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is focusing on evaluating the peripheral immune system of major depressive disorder (MDD) and the impact of antidepressants treatment. Single-cell RNA sequencing and single-cell VDJ sequencing will be performed on peripheral blood mononuclear cells to collect transcriptome information and immune repertoire of peripheral blood in patients with MDD. Bulk RNA sequencing and flow cytometry will be used to validate the clinical value of results.
This is a biomarker study (antidepressants); treatment will be carried out according to physicians' orders.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Huangfang Li
- Phone Number: +86-2134773128
- Email: lihuafang@smhc.org.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Mental Health Center
-
Contact:
- Huafang Li, PH.D
- Phone Number: 86-2134773128
- Email: lhlh_5@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18-65 years old, regardless of gender;
- The subject is an outpatient/inpatient and meets DSM-5 diagnostic criteria of current or past major depressive disorder;
- SSRIs or SNRIs monotherapy;
- HAMD-17 total score ≥ 18 at baseline;
- The subject can read and write and is capable of giving informed consent.
Exclusion Criteria:
- Patients with mental illness other than MDD;
- Patients with liver and kidney diseases, cardiovascular system diseases, cancer, diabetes, thyroid diseases or other serious or unstable conditions;
- Previous organic brain disease, traumatic brain injury or other diseases that can cause structural brain changes;
- Serious abnormalities indicated by laboratory tests or electrocardiograms;
- Alcohol or drug addiction;
- Suffering from systemic lupus erythematosus, multiple sclerosis or other autoimmune diseases;
- Patients who are taking drugs that directly impact on the immune system such as anti-inflammatory drugs or immunosuppressants;
- Patients who have taken antidepressants or other antipsychotics within 2 weeks before enrollment;
- Patients who have received MECT or systematic psychotherapy within 3 months before enrollment;
- Patients at high risk of suicide, or reporting a HAMD-17 item 3 (suicide item) score >3 at baseline;
- Subjects who are pregnant or lactating;
- Other conditions that are considered not suitable for participating in the research.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Major Depressive Disorder (MDD)
Patients with major depressive disorder.
These patients consisted of two cohorts.
The first cohort is expected to consist of 15 participants for nested cohort study.
The rest form the second cohort.
|
Patients will receive psychiatric rating scales evaluation every visit.
Other Names:
|
Healthy controls
Healthy normal volunteers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of HAMD-17 (Hamilton Depression Rating Scale) total score
Time Frame: From baseline to Week 8
|
The overall score of HAMD-17 (Hamilton Depression Rating Scale) is 68 points.
Primary outcome measures the change of HAMD-17 total score between baseline and week 8. Larger reduction in HAMD-17 represents better antidepressant treatment response.
|
From baseline to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effective rate measured by HAMD-17 (Hamilton Depression Rating Scale)
Time Frame: From baseline to Week 8
|
A reduction of 50% or more in the HAMD-17 (Hamilton Depression Rating Scale) total score.
More patients with a reduction of 50% or more indicates better effectiveness.
Minimun value of HAMD-17 is 0 and maximum value of HAMD-17 is 68 points.
|
From baseline to Week 8
|
MADRS Effective rate measured by MADRS (Montgomery-Åsberg depression rating scale)
Time Frame: From baseline to Week 8
|
A reduction of 50% or more in the MADRS (Montgomery-Åsberg depression rating scale) total score.
More patients with a reduction of 50% or more indicates better effectiveness.
Minimun value of MADRS is 0 and maximum value of MADRS is 60 points.
|
From baseline to Week 8
|
Remission rate measured by HAMD-17 (Hamilton Depression Rating Scale)
Time Frame: From baseline to Week 8
|
HAMD-17 (Hamilton Depression Rating Scale) total score ≤10 at week8.
Lower total score of HAMD-17 at week 8 indicates better outcome.
Minimun value of HAMD-17 is 0 and maximum value of HAMD-17 is 68 points.
|
From baseline to Week 8
|
MADRS Remission rate measured by MADRS (Montgomery-Åsberg depression rating scale)
Time Frame: From baseline to Week 8
|
MADRS (Montgomery-Åsberg depression rating scale) total score ≤7 at week8.
Lower total score of HAMD-17 at week 8 indicates better outcome.
Minimun value of MADRS is 0 and maximum value of MADRS is 60 points.
|
From baseline to Week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HAMD-17 (Hamilton Depression Rating Scale) total score
Time Frame: Baseline, Week 2, Week 4 and Week 8.
|
Minimun value of HAMD-17 (Hamilton Depression Rating Scale) is 0 and maximum value of HAMD-17 is 68 points.
Higher scores implies higher severity.
|
Baseline, Week 2, Week 4 and Week 8.
|
MADRS (Montgomery-Åsberg depression rating scale) total score
Time Frame: Baseline, Week 2, Week 4 and Week 8.
|
Minimun value of MADRS (Montgomery-Åsberg depression rating scale) is 0 and maximum value of MADRS is 60 points.
Higher scores implies higher severity.
|
Baseline, Week 2, Week 4 and Week 8.
|
CGI-S (Clinical Gloabl Impression-Severity) score
Time Frame: Baseline, Week 2, Week 4 and Week 8.
|
Minimun value of CGI-S (Clinical Gloabl Impression-Severity) is 0 and maximum value of CGI-S is 7 points.
Higher scores implies higher severity.
|
Baseline, Week 2, Week 4 and Week 8.
|
CGI-I (Clinical Gloabl Impression-Improvement) score
Time Frame: Baseline, Week 2, Week 4 and Week 8.
|
Minimun value of CGI-I (Clinical Gloabl Impression-Improvement) is 1 points and maximum value of CGI-I is 7 points.
Higher scores implies worse outcome.
|
Baseline, Week 2, Week 4 and Week 8.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Shen He, Shanghai Mental Health Center
Publications and helpful links
General Publications
- Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, Kang B, Hu R, Huang JY, Zhang Q, Liu Z, Dong M, Hu X, Ouyang W, Peng J, Zhang Z. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017 Jun 15;169(7):1342-1356.e16. doi: 10.1016/j.cell.2017.05.035.
- Malhi GS, Mann JJ. Depression. Lancet. 2018 Nov 24;392(10161):2299-2312. doi: 10.1016/S0140-6736(18)31948-2. Epub 2018 Nov 2.
- Kato T, Furukawa TA, Mantani A, Kurata K, Kubouchi H, Hirota S, Sato H, Sugishita K, Chino B, Itoh K, Ikeda Y, Shinagawa Y, Kondo M, Okamoto Y, Fujita H, Suga M, Yasumoto S, Tsujino N, Inoue T, Fujise N, Akechi T, Yamada M, Shimodera S, Watanabe N, Inagaki M, Miki K, Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Shinohara K, Yonemoto N, Tanaka S, Zhou Q, Guyatt GH; SUN☺D Investigators. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med. 2018 Jul 11;16(1):103. doi: 10.1186/s12916-018-1096-5.
- Leday GGR, Vertes PE, Richardson S, Greene JR, Regan T, Khan S, Henderson R, Freeman TC, Pariante CM, Harrison NA; MRC Immunopsychiatry Consortium; Perry VH, Drevets WC, Wittenberg GM, Bullmore ET. Replicable and Coupled Changes in Innate and Adaptive Immune Gene Expression in Two Case-Control Studies of Blood Microarrays in Major Depressive Disorder. Biol Psychiatry. 2018 Jan 1;83(1):70-80. doi: 10.1016/j.biopsych.2017.01.021. Epub 2017 Jul 6.
- Nohr AK, Lindow M, Forsingdal A, Demharter S, Nielsen T, Buller R, Moltke I, Vitezic M, Albrechtsen A. A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with major depressive disorder. Neuropsychopharmacology. 2021 Jun;46(7):1324-1332. doi: 10.1038/s41386-021-01002-9. Epub 2021 Apr 8.
- Cattaneo A, Ferrari C, Turner L, Mariani N, Enache D, Hastings C, Kose M, Lombardo G, McLaughlin AP, Nettis MA, Nikkheslat N, Sforzini L, Worrell C, Zajkowska Z, Cattane N, Lopizzo N, Mazzelli M, Pointon L, Cowen PJ, Cavanagh J, Harrison NA, de Boer P, Jones D, Drevets WC, Mondelli V, Bullmore ET; Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) Consortium; Pariante CM. Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODEP study. Transl Psychiatry. 2020 Jul 23;10(1):232. doi: 10.1038/s41398-020-00874-7. Erratum In: Transl Psychiatry. 2020 Oct 19;10(1):352.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-TX-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Mental assessments
-
Fondation LenvalCompleted
-
Washington University School of MedicineUnknownMental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)United States
-
Afyonkarahisar Health Sciences UniversityCompleted
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)CompletedMood Disorders | Hypertension | Sleep | Overweight and Obesity | Vascular Stiffness | Elevated Blood PressureUnited States
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertension | Sleep | Prehypertension | Endothelial Dysfunction | Overweight and Obesity | Vascular Stiffness | Elevated Blood PressureUnited States
-
Institut National de la Santé Et de la Recherche...University College, LondonCompletedHuntington Disease | White Matter AlterationsFrance
-
National Heart Centre SingaporeSingapore National Eye CentreUnknownMicroalbuminuria | Diastolic Dysfunction | Retinopathy, DiabeticSingapore
-
Swiss Tropical & Public Health InstituteWorld BankActive, not recruitingCompliant Behavior | Morbidity;InfantSwitzerland, Congo, The Democratic Republic of the
-
University Health Network, TorontoRecruiting
-
Dokuz Eylul UniversityRecruitingRestless Legs Syndrome | Neuromyelitis OpticaTurkey